Lilly raises 2020 earnings forecast on pandemic stockpilingStockpiling of drugs for chronic diseases like diabetes during the coronavirus pandemic lifted Eli Lilly’s first-quarter results, and Share XLilly raises 2020 earnings forecast on pandemic stockpilinghttps://pharmaphorum.com/news/lilly-raises-2020-earnings-forecast-on-pandemic-stockpiling/
Novartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthritisBeating AbbVie’s TNF blocker Humira in a head-to-head trial has become a rite of passage for new interleukin-targeting Share XNovartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthritishttps://pharmaphorum.com/news/novartis-cosentyx-cant-exceed-humira-in-psoriatic-arthritis/
Lilly dips as biomed chief Christi Shaw heads to GileadChristi Shaw, president of Eli Lilly Bio-Medicines is leaving the company after two years, taking the top job Share XLilly dips as biomed chief Christi Shaw heads to Gileadhttps://pharmaphorum.com/news/lilly-dips-as-biomed-chief-christi-shaw-heads-to-gilead/
Lilly’s Taltz scrapes win against Humira in psoriatic arthritisEli Lilly’s Taltz has beaten AbbVie’s blockbuster Humira in a psoriatic arthritis study involving patients who hadn’t been Share XLilly’s Taltz scrapes win against Humira in psoriatic arthritishttps://pharmaphorum.com/news/lillys-taltz-scrapes-win-against-humira-in-psoriatic-arthritis/
